Aquestive Therapeutics Inc (AQST) ニュース

Form 8-K - Current report

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025Actively recruiting subjects in the...

Form 8-K - Current report

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Form 8-K - Current report

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine...

Form 8-K - Current report